Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms VESTA
- Sponsors AbbVie; AbbVie Germany
- 16 Oct 2019 Planned number of patients changed from 970 to 975.
- 09 Aug 2019 Status changed from active, no longer recruiting to completed.
- 22 May 2019 This trial has been completed in Norway, according to European Clinical Trials Database.